Cargando…

Performance Characteristics of the BluePrint® Breast Cancer Diagnostic Test()

The analytical performance of a multi-gene diagnostic signature depends on many parameters, including precision, repeatability, reproducibility and intra-tumor heterogeneity. Here we study the analytical performance of the BluePrint 80-gene breast cancer molecular subtyping test through determinatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Mittempergher, Lorenza, Delahaye, Leonie JMJ, Witteveen, Anke T, Snel, Mireille HJ, Mee, Sammy, Chan, Bob Y, Dreezen, Christa, Besseling, Naomi, Luiten, Ernest JT
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7097521/
https://www.ncbi.nlm.nih.gov/pubmed/32208353
http://dx.doi.org/10.1016/j.tranon.2020.100756
_version_ 1783511013758337024
author Mittempergher, Lorenza
Delahaye, Leonie JMJ
Witteveen, Anke T
Snel, Mireille HJ
Mee, Sammy
Chan, Bob Y
Dreezen, Christa
Besseling, Naomi
Luiten, Ernest JT
author_facet Mittempergher, Lorenza
Delahaye, Leonie JMJ
Witteveen, Anke T
Snel, Mireille HJ
Mee, Sammy
Chan, Bob Y
Dreezen, Christa
Besseling, Naomi
Luiten, Ernest JT
author_sort Mittempergher, Lorenza
collection PubMed
description The analytical performance of a multi-gene diagnostic signature depends on many parameters, including precision, repeatability, reproducibility and intra-tumor heterogeneity. Here we study the analytical performance of the BluePrint 80-gene breast cancer molecular subtyping test through determination of these performance characteristics. BluePrint measures the expression of 80 genes that assess functional pathways which determine the intrinsic breast cancer molecular subtypes (i.e. Luminal-type, HER2-type, Basal-type). Knowing a tumor's dominant functional pathway can help allocate effective treatment to appropriate patients. Here we show that BluePrint is a highly precise and highly reproducible test with correlations above 98% based on the generated index and subtype concordance above 99%. Therefore, BluePrint can be used as a robust and reliable tool to identify breast cancer molecular subtypes.
format Online
Article
Text
id pubmed-7097521
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Neoplasia Press
record_format MEDLINE/PubMed
spelling pubmed-70975212020-03-27 Performance Characteristics of the BluePrint® Breast Cancer Diagnostic Test() Mittempergher, Lorenza Delahaye, Leonie JMJ Witteveen, Anke T Snel, Mireille HJ Mee, Sammy Chan, Bob Y Dreezen, Christa Besseling, Naomi Luiten, Ernest JT Transl Oncol Original article The analytical performance of a multi-gene diagnostic signature depends on many parameters, including precision, repeatability, reproducibility and intra-tumor heterogeneity. Here we study the analytical performance of the BluePrint 80-gene breast cancer molecular subtyping test through determination of these performance characteristics. BluePrint measures the expression of 80 genes that assess functional pathways which determine the intrinsic breast cancer molecular subtypes (i.e. Luminal-type, HER2-type, Basal-type). Knowing a tumor's dominant functional pathway can help allocate effective treatment to appropriate patients. Here we show that BluePrint is a highly precise and highly reproducible test with correlations above 98% based on the generated index and subtype concordance above 99%. Therefore, BluePrint can be used as a robust and reliable tool to identify breast cancer molecular subtypes. Neoplasia Press 2020-03-21 /pmc/articles/PMC7097521/ /pubmed/32208353 http://dx.doi.org/10.1016/j.tranon.2020.100756 Text en © 2020 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original article
Mittempergher, Lorenza
Delahaye, Leonie JMJ
Witteveen, Anke T
Snel, Mireille HJ
Mee, Sammy
Chan, Bob Y
Dreezen, Christa
Besseling, Naomi
Luiten, Ernest JT
Performance Characteristics of the BluePrint® Breast Cancer Diagnostic Test()
title Performance Characteristics of the BluePrint® Breast Cancer Diagnostic Test()
title_full Performance Characteristics of the BluePrint® Breast Cancer Diagnostic Test()
title_fullStr Performance Characteristics of the BluePrint® Breast Cancer Diagnostic Test()
title_full_unstemmed Performance Characteristics of the BluePrint® Breast Cancer Diagnostic Test()
title_short Performance Characteristics of the BluePrint® Breast Cancer Diagnostic Test()
title_sort performance characteristics of the blueprint® breast cancer diagnostic test()
topic Original article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7097521/
https://www.ncbi.nlm.nih.gov/pubmed/32208353
http://dx.doi.org/10.1016/j.tranon.2020.100756
work_keys_str_mv AT mittempergherlorenza performancecharacteristicsoftheblueprintbreastcancerdiagnostictest
AT delahayeleoniejmj performancecharacteristicsoftheblueprintbreastcancerdiagnostictest
AT witteveenanket performancecharacteristicsoftheblueprintbreastcancerdiagnostictest
AT snelmireillehj performancecharacteristicsoftheblueprintbreastcancerdiagnostictest
AT meesammy performancecharacteristicsoftheblueprintbreastcancerdiagnostictest
AT chanboby performancecharacteristicsoftheblueprintbreastcancerdiagnostictest
AT dreezenchrista performancecharacteristicsoftheblueprintbreastcancerdiagnostictest
AT besselingnaomi performancecharacteristicsoftheblueprintbreastcancerdiagnostictest
AT luitenernestjt performancecharacteristicsoftheblueprintbreastcancerdiagnostictest
AT performancecharacteristicsoftheblueprintbreastcancerdiagnostictest